Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for glucosamine, the scientific conclusions are as follows: Further to a review of concomitant uses of glucosamine with oral vitamin K antagonists, the PRAC concluded that the provided dataset supports evidence of interactions which may lead to an increase of the International Normalised Ratio (INR) after patients receiving coumarin anticoagulants began taking glucosamine, which indicates an increase in the coagulation time. Whilst acknowledging that there is insufficient information to conclude on a mechanism for an interaction between glucosamine and coumarin anticoagulants, the Committee notices the evidence of an interaction between glucosamine and coumarin anticoagulants by the observation that in the majority of cases the INR began to fall to normal values when glucosamine intake is discontinued. The Committee therefore agreed that amendments to the sections 4.5 of the SmPC are warranted for the glucosamine and oral vitamin K antagonists interaction. The Package leaflet is updated accordingly. Therefore, in view of the data presented in the reviewed PSURs, the PRAC considered that changes to the product information of medicinal products containing glucosamine, were warranted. The CMDh agrees with the scientific conclusions made by the PRAC.
Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for glucosamine the CMDh is of the opinion that the benefitrisk balance of the medicinal product(s) containing glucosamine is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing glucosamine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.
Annex II Amendments to the product information of the nationally authorised medicinal product(s)
Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through)
Summary of Product Characteristics •
Section 4.5
The following statement should be added: There are limited data on possible drug interactions with glucosamine, but increments in the INR parameter have been reported with oral vitamin K antagonists. Patients treated with oral vitamin K antagonists should therefore be closely monitored at the time of initiation or termination of glucosamine therapy.
glucosamine,: CMDh scientific conclusions and grounds for the ...
27 Jan 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for glucosamine, the scientific ... insufficient information to conclude on a mechanism for an interaction between glucosamine and coumarin ... the product information of medicinal products containing glucosamine, were warranted.
Dec 22, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron ... Annex III. Timetable for the implementation of this position ...
Jun 9, 2018 - Based on a comprehensive review of âparaesthesiaâ, including ... of hypersensitivity reactions to chrysanthemums including literature ...
Aug 5, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... for the variation to the terms of the Marketing Authorisation(s) ... Page 3 ...
Jun 9, 2018 - peak toxicity and prolonged recovery when compared to immediate-release (IR) quetiapine overdose: a retrospective cohort study. Clinical ...
Nov 25, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for saccharomyces boulardii, the scientific ... patients is considered changed and an update of the product information is warranted. ... relevant sections of the SmPC (sect
Jun 4, 2017 - Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the scientific conclusions for finasteride the CMDh is of ...
Mar 10, 2018 - trace residue from the manufacturing process), or to any of the excipients., or The the stopper of the glass vial with Actilyse powder which contains natural rubber (a derivative of latex). which may cause allergic reactions. No sustai
Dec 27, 2017 - for anxiety in one case and taking into account the listedness of these adverse reactions in the product information of other progestin only medicinal products, the lead member state considers that anxiety and depression should be incl
Nov 25, 2017 - Allergic reactions the signs of which may include difficulty in breathing, dizziness, collapsing or losing consciousness, swelling of your face, lips ...
27 Jan 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for lanthanum, the scientific ... this PSUR, the PRAC considers that the product information of lanthanum containing medicinal products should be ... Amendments to the produc
Oct 28, 2017 - Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for quinine, the scientific conclusions are as follows: Atrioventricular block ... The PRAC considers that the above information is relevant and ther
Taking into account the PRAC Assessment Report on the PSUR(s) for ivermectin (topical use), the scientific conclusions are as follows: During the reporting period, ... Amendments to be included in the relevant sections of the Product Information (new
Nov 26, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for gabapentin, ... Annex III. Timetable for the implementation of this position ...
Mar 11, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) ... 3. Grounds for the variation to the terms of the Marketing Authorisation(s).
Jan 28, 2017 - Therefore, in view of the data presented in the reviewed PSUR(s), the ... The CMDh reaches the position that the marketing authorisation(s) of ...
Due to the existing structural homology between oxytocin and latex, latex allergy/intolerance may be an important predisposing risk factor for anaphylaxis.
28 Oct 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for diacerein, the scientific ... Based on the information presented in this PSUR, PRAC considered that section 4.8 of the Summary of. Product ... Amendments to be included i
Dec 23, 2017 - 2. Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for sodium iodide (131i), the scientific conclusions are as follows: ... do contribute to the phenomenon in this specific patient group and theref
Nov 25, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for bilastine, the scientific conclusions are as follows: During the reporting interval a ... hypersensitivity reactions should be included in the product information for bi
Jan 27, 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for cefuroxime sodium (except for ... cefuroxime sodium (except for intracameral use) is unchanged subject to the proposed changes to the product information. The CMDh reach
Jun 9, 2018 - Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through).
Mar 11, 2017 - monitoring of immunosuppressant tacrolimus (sirolimus and cyclosporine) in presence of the concomitant administration of nicardipine to ...
Mar 12, 2018 - If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect may not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an u